RecruitingNot ApplicableNCT06769165

EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors

EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors - a Pilot Study


Sponsor

University Medical Center Groningen

Enrollment

20 participants

Start Date

Jul 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.


Eligibility

Min Age: 16 Years

Inclusion Criteria5

  • Previously pathologically confirmed diagnosis of cancer
  • Previously treated with systemic cancer therapy
  • Persistent complaints (more than 2 months) of conditioned nausea and/or vomiting
  • Able to understand spoken and written Dutch
  • years or older

Exclusion Criteria4

  • Ongoing psychiatric treatment
  • EMDR therapy contraindications (dissociative disorders, personality disorders or severe somatic disorders (e.g. cardiac arrhythmias))
  • Complex type 2 trauma
  • Known with recent conditions / non-anti-cancer medication which can elicit nausea (e.g. pregnancy or alcohol abuses)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREMDR therapy

In this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.


Locations(1)

University Medical Center Groningen

Groningen, Provincie Groningen, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06769165


Related Trials